Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma
- 27 June 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 133 (26) , 2776-2789
Abstract
Anaplastic large cell lymphomas (ALCLs) represent a relatively common group of T-cell non-Hodgkin lymphomas (T-NHLs) that are unified by similar pathologic features but demonstrate marked genetic heterogeneity. ALCLs are broadly classified as being anaplastic lymphoma kinase (ALK)+ or ALK−, based on the presence or absence of ALK rearrangements. Exome sequencing of 62 T-NHLs identified a previously unreported recurrent mutation in the musculin gene, MSCE116K, exclusively in ALK− ALCLs. Additional sequencing for a total of 238 T-NHLs confirmed the specificity of MSCE116K for ALK− ALCL and further demonstrated that 14 of 15 mutated cases (93%) had coexisting DUSP22 rearrangements. Musculin is a basic helix-loop-helix (bHLH) transcription factor that heterodimerizes with other bHLH proteins to regulate lymphocyte development. The E116K mutation localized to the DNA binding domain of musculin and permitted formation of musculin–bHLH heterodimers but prevented their binding to authentic target sequence. Functional analysis showed MSCE116K acted in a dominant-negative fashion, reversing wild-type musculin-induced repression of MYC and cell cycle inhibition. Chromatin immunoprecipitation–sequencing and transcriptome analysis identified the cell cycle regulatory gene E2F2 as a direct transcriptional target of musculin. MSCE116K reversed E2F2-induced cell cycle arrest and promoted expression of the CD30–IRF4–MYC axis, whereas its expression was reciprocally induced by binding of IRF4 to the MSC promoter. Finally, ALCL cells expressing MSCE116K were preferentially targeted by the BET inhibitor JQ1. These findings identify a novel recurrent MSC mutation as a key driver of the CD30–IRF4–MYC axis and cell cycle progression in a unique subset of ALCLs.Keywords
This publication has 65 references indexed in Scilit:
- A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR– B cellsJournal of Clinical Investigation, 2013
- Structural Basis for LMO2-Driven Recruitment of the SCL:E47bHLH Heterodimer to Hematopoietic-Specific Transcriptional TargetsCell Reports, 2013
- BATF–JUN is critical for IRF4-mediated transcription in T cellsNature, 2012
- Genomic loss of the putative tumor suppressor gene E2A in human lymphomaJournal of Experimental Medicine, 2011
- Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencingBlood, 2011
- Myristoylation of the dual‐specificity phosphatase c‐JUN N‐terminal kinase (JNK) stimulatory phosphatase 1 is necessary for its activation of JNK signaling and apoptosisThe FEBS Journal, 2010
- Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomasLeukemia, 2008
- The anaplastic lymphoma kinase in the pathogenesis of cancerNature Reviews Cancer, 2008
- Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesisProceedings of the National Academy of Sciences, 2007
- The Dual Specificity JKAP Specifically Activates the c-Jun N-terminal Kinase PathwayJournal of Biological Chemistry, 2002